Evonik Announces New Performance-Oriented Corporate Culture
By making its portfolio more specialty, strengthening its innovation power and driving a performance-oriented corporate culture, Evonik strives to build a best-in-class specialty chemicals company. CEO Christian Kullmann have announced various measures to achieve these goals.
"I am excited at the opportunities that lie ahead for Evonik,” Kullmann told analysts and investors at a strategy update in London. "We will enhance value creation for our stakeholders by sharpening our focus on specialty chemicals, driving innovation and encouraging a trustful corporate culture of measured risk-taking.”
Higher range of EBITDA
With the help of these three levers, Evonik aims to grow sales volumes faster than global GDP. At the same time the company plans to lift its adjusted EBITDA margin into a sustainably higher range of 18 -20 percent, from a historic range of around 16-18 percent. "We want to focus more strongly on businesses with a clear specialty chemicals character,” said Kullmann. "Going forward our portfolio will have a higher share of growth businesses.”
Four areas with margin potential
The company has identified four areas – specialty additives, animal nutrition, smart materials and health care - that have above-average growth and margin potential. These will be the focus of capital allocation. "Active portfolio management with regular strategic reviews as well as improved cost competitiveness will help the group achieve its growth and margin goals,” emphasised Chief Financial Officer Ute Wolf.
Increasing sales of younger products
Evonik’s innovation pipeline will also drive improving profitability. The goal is for products and applications younger than five years to make up 16 percent of sales in the medium term. The company will sharpen the focus of its activities by intensifying collaboration with customers and along value chains. The company aims for a corporate culture in which employees will take action and initiate change. The goal is to develop a more international and diverse mind-set that builds on trust, respect and openness.
Management board complements strengths
The new four-member management board will form a strong and aligned team with complementing strengths. Along with Christian Kullmann (48), Harald Schwager (56) will be joining Evonik on September 1 as the new deputy chairman of the executive board with responsibility for chemicals and innovation. Ute Wolf (49) and Thomas Wessel (54) will continue in their roles as Chief Financial Officer and Chief Human Resources Officer respectively.
2026-07-27
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Multiple Chemical Industry Leaders Post Strong H1 Earnings Growth as Sector Profitability Revives
-
Evonik Inaugurates New Speciality Alumina Plant in Japan, Bolstering Regional Growth Strategy
-
Evonik and AMSilk Expand Collaboration to Develop Sustainable Biotech Silk Materials
-
Evonik Launches Asia’s First Alkoxide Plant in Jurong Island
-
Evonik Converts Epoxy Hardener Production to 100% Renewable Electricity
-
Breakup! Vland Biotech and Evonik Part Ways as GHS Joint Venture Falls Short of Expectations
-
Evonik Completes Shift to Green Electricity for Polybutadiene Production at its Marl, Germany, Plant
-
Evonik Expands Polybutadiene Production Capacity in China
-
Evonik launches particle dispersion portfolio to improve resolution of inkjet ink coatings
-
Evonik Coating Additives Launches First Mass Balance Products for Coatings and Inks
Recommend Reading
-
Roche Takes Natco to Supreme Court Over Generic Risdiplam Launch in India
-
India Terminates Anti-Dumping Investigation on Chinese Siloxane Polyoxyalkylene Copolymers
-
INEOS Plant Closures Deepen Europe’s Chemical Industry Crisis
-
Dow Chemical’s Freeport Plant Fire Contained; No Injuries Reported
-
Bayer’s Ambitious Gene & Cell Therapy Pipeline Eyes Parkinson’s, Oncology, Rare Diseases
-
China's acetone export volume continued to grow from January to July 2025
-
Terminal demand weak, adipic acid market trend declines
-
This Round of Refined Oil Retail Prices in China Will See a 'Triple Increase'
-
Coke market prices show strong performance in China
-
Insufficient Demand for Cyclohexane in China, Weak Market Situation Persists